Pimobendan increases survival of cardiomyopathic hamsters.
Article Details
- CitationCopy to clipboard
van Meel JC, Mauz AB, Wienen W, Diederen W
Pimobendan increases survival of cardiomyopathic hamsters.
J Cardiovasc Pharmacol. 1989 Mar;13(3):508-9.
- PubMed ID
- 2471899 [ View in PubMed]
- Abstract
We investigated the effect of the new cardiotonic drug pimobendan on survival of hereditary cardiomyopathic hamsters. Untreated cardiomyopathic hamsters served as controls. A 50% mortality was observed after 280 days for the control group and after 318 days for the pimobendan-treated animals. After 340 days, survival was 0% for the untreated cardiomyopathic hamsters and 27% in the pimobendan-treated group. We conclude that pimobendan slows the progression of heart failure in cardiomyopathic hamsters.
DrugBank Data that Cites this Article
- Drugs